Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Initiation

Initiation

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Analyst Ratings
  • Initiation
  • News
  • Price Target

B. Riley Securities Initiates Coverage On Paragon 28 with Buy Rating, Announces Price Target of $32

By Benzinga Newsdesk
December 14, 4:02 PM
B. Riley Securities analyst Neil Chatterji initiates coverage on Paragon 28 (NYSE:FNA) with a Buy rating and announces Price Target of $32.

FNA

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • General
  • Health Care
  • Initiation
  • Movers
  • News
  • Price Target
  • Small Cap
  • Trading Ideas

Analyst Bullish On Theseus Pharma’s Platform For Gastric Cancer Therapies

By Vandana Singh
December 14, 2:20 PM
Needham has initiated coverage on Theseus Pharmaceuticals Inc (NASDAQ:THRX) with a Buy rating and a price target of $22. Theseus’ discovery platform…

DCPH

Read More
1 minute read
  • Analyst Ratings
  • Initiation
  • News
  • Price Target

Exane BNP Paribas Initiates Coverage On Radius Global Infr with Outperform Rating, Announces Price Target of $17

By Benzinga Newsdesk
December 14, 11:20 AM
Exane BNP Paribas analyst Nate Crossett initiates coverage on Radius Global Infr (NASDAQ:RADI) with a Outperform rating and announces Price Target of $17.

RADI

Read More
1 minute read
  • Analyst Ratings
  • Initiation
  • News
  • Price Target

Exane BNP Paribas Initiates Coverage On Equinix with Outperform Rating, Announces Price Target of $886

By Benzinga Newsdesk
December 14, 11:18 AM
Exane BNP Paribas analyst Nate Crossett initiates coverage on Equinix (NASDAQ:EQIX) with a Outperform rating and announces Price Target of $886.

EQIX

Read More
1 minute read
  • Analyst Ratings
  • Initiation
  • News
  • Price Target

UBS Initiates Coverage On Calumet Specialty with Neutral Rating, Announces Price Target of $15.7

By Benzinga Newsdesk
December 14, 10:16 AM
UBS analyst Manav Gupta initiates coverage on Calumet Specialty (NASDAQ:CLMT) with a Neutral rating and announces Price Target of $15.7.

CLMT

Read More
1 minute read
  • Analyst Ratings
  • Initiation
  • News
  • Price Target

Cowen & Co. Initiates Coverage On Simply Good Foods with Market Perform Rating, Announces Price Target of $42

By Benzinga Newsdesk
December 14, 9:40 AM
Cowen & Co. analyst Brian Holland initiates coverage on Simply Good Foods (NASDAQ:SMPL) with a Market Perform rating and announces Price Target of $42.

SMPL

Read More
1 minute read
  • Analyst Ratings
  • Initiation
  • News

Deutsche Bank Initiates Coverage On Abcam with Hold Rating

By Benzinga Newsdesk
December 14, 9:28 AM
Deutsche Bank analyst Justin Bowers initiates coverage on Abcam (NASDAQ:ABCM) with a Hold rating.

ABCM

Read More
1 minute read
  • Analyst Ratings
  • Initiation
  • News
  • Price Target

Credit Suisse Assumes FirstCash Hldgs at Neutral, Announces Price Target of $88

By Benzinga Newsdesk
December 14, 9:27 AM
Credit Suisse analyst Moshe Orenbuch assumes FirstCash Hldgs (NASDAQ:FCFS) with a Neutral rating and announces Price Target of $88.

FCFS

Read More
1 minute read
  • Analyst Ratings
  • Initiation
  • News
  • Price Target

Raymond James Initiates Coverage On POINT Biopharma Global with Outperform Rating, Announces Price Target of $10

By Benzinga Newsdesk
December 14, 9:19 AM
Raymond James analyst Rahul Sarugaser initiates coverage on POINT Biopharma Global (NASDAQ:PNT) with a Outperform rating and announces Price Target of $10.

PNT

Read More
1 minute read
  • Analyst Ratings
  • Initiation
  • News
  • Price Target

Needham Initiates Coverage On Revolution Medicines with Buy Rating, Announces Price Target of $31

By Benzinga Newsdesk
December 14, 8:53 AM
Needham analyst Ami Fadia initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Buy rating and announces Price Target of $31.

RVMD

Posts pagination

Previous 1 … 119 120 121 … 272 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service